- INVESTMENT OPPORTUNITIES
- SECONDARY MARKET
Small molecules and oral administration could clearly be a competitive advantage. Serious infections will continue to be a huge and growing market.
The target is well known, but only antibodies have reached the market so far. The strategy of modulating the target with small molecules is very innovative.
At the present stage, it is a solid team with a long experience. The company has a high potential due to the importance of its primary indication.
This is the final investment you will make. The amount you have entered has probably been rounded to match the share price.